{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:52:26Z","timestamp":1789455146668,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,15]]},"DOI":"10.1093\/cid\/cix358","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T03:10:53Z","timestamp":1492744253000},"page":"551-556","source":"Crossref","is-referenced-by-count":17,"title":["Viral Kinetics in Semen With Different Antiretroviral Families in Treatment-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Trial"],"prefix":"10.1093","volume":"65","author":[{"given":"Alicia","family":"Gutierrez-Valencia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar J.","family":"Benmarzouk-Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Rivas-Jerem\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Trujillo-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Fernandez-Magdaleno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pompeyo","family":"Viciana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,4,25]]},"reference":[{"key":"key\n\t\t\t\t20170801105421_CIT0001","first-page":"77ra29","article-title":"Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission","volume":"3","year":"2011","journal-title":"Sci Transl Med"},{"key":"key\n\t\t\t\t20170801105421_CIT0002","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(12)61898-4","article-title":"Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003\u201311): a national observational cohort study","volume":"382","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170801105421_CIT0003","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cid\/civ200","article-title":"Treatment to prevent HIV transmission in serodiscordant couples in Henan, China, 2006 to 2012","volume":"61","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170801105421_CIT0004","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jama.2016.5148","article-title":"Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy","volume":"316","author":"PARTNER Study Group","year":"2016","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170801105421_CIT0005","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1600693","article-title":"Antiretroviral therapy for the prevention of HIV-1 transmission","volume":"375","author":"HPTN 052 Study Team","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170801105421_CIT0006","author":"European AIDS Clinical Society (EACS)"},{"key":"key\n\t\t\t\t20170801105421_CIT0007","volume-title":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2016"},{"key":"key\n\t\t\t\t20170801105421_CIT0008","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/QAD.0000000000000060","article-title":"Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir\/ritonavir monotherapy","volume":"28","year":"2014","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170801105421_CIT0009","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/jms.3200","article-title":"A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients","volume":"48","year":"2013","journal-title":"J Mass Spectrom"},{"key":"key\n\t\t\t\t20170801105421_CIT0010","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/sim.1505","article-title":"Estimating correlation by using a general linear mixed model: evaluation of the relationship between the concentration of HIV-1 RNA in blood and semen","volume":"22","year":"2003","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20170801105421_CIT0011","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/387188a0","article-title":"Decay characteristics of HIV-1-infected compartments during combination therapy","volume":"387","year":"1997","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170801105421_CIT0012","doi-asserted-by":"crossref","first-page":"e43086","DOI":"10.1371\/journal.pone.0043086","article-title":"HIV-1 RNA may decline more slowly in semen than in blood following initiation of efavirenz-based antiretroviral therapy","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170801105421_CIT0013","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"379","author":"GS-236-0103 Study Team","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170801105421_CIT0014","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"GS-US-236-0102 study team","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170801105421_CIT0015","first-page":"225","article-title":"Elvitegravir concentrations in seminal plasma in HIV-1-infected men","volume":"18","year":"2016","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20170801105421_CIT0016","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jac\/dku018","article-title":"Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy","volume":"69","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170801105421_CIT0017","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1097\/QAD.0b013e32833ead18","article-title":"Darunavir concentrations exceed the protein-corrected EC\u2085\u2080 for wild-type HIV in the semen of HIV-1-infected men","volume":"24","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170801105421_CIT0018","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1128\/AAC.01235-13","article-title":"Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170801105421_CIT0019","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/jac\/dku575","article-title":"Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults","volume":"70","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170801105421_CIT0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11584570-000000000-00000","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir","volume":"50","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20170801105421_CIT0021","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/AAC.00986-09","article-title":"TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1","volume":"54","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170801105421_CIT0022","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1086\/344311","article-title":"Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men","volume":"186","year":"2002","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170801105421_CIT0023","doi-asserted-by":"crossref","first-page":"e43086","DOI":"10.1371\/journal.pone.0043086","article-title":"HIV-1 RNA may decline more slowly in semen than in blood following initiation of efavirenz-based antiretroviral therapy","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170801105421_CIT0024","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/infdis\/jiw406","article-title":"HIV-1-RNA Decay and dolutegravir concentrations in semen of patients starting a first antiretroviral regimen","volume":"214","year":"2016","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170801105421_CIT0025","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1097\/QAD.0b013e3283303e04","article-title":"Persistent HIV RNA shedding in semen despite effective antiretroviral therapy","volume":"23","author":"Toronto Mucosal Immunology Group","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170801105421_CIT0026","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/QAD.0b013e328352ae09","article-title":"Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002\u20132011 survey","volume":"26","year":"2012","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170801105421_CIT0027","doi-asserted-by":"crossref","first-page":"98.e7","DOI":"10.1016\/j.cmi.2015.09.028","article-title":"Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract","volume":"22","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20170801105421_CIT0028","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/infdis\/jiw131","article-title":"Seminal HIV-1 RNA detection in heterosexual African men initiating antiretroviral therapy","volume":"214","author":"Partners PrEP Study Team","year":"2016","journal-title":"J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/65\/4\/551\/19378720\/cix358.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T19:05:04Z","timestamp":1503601504000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/cix358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,25]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4,25]]},"published-print":{"date-parts":[[2017,8,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix358","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,25]]}}}